• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

ESMO: Seagen's Padcev pulls its weight in combo with Merck's Keytruda

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 08, 2022 at 05:02: PM
via The combination of Merck’s Keytruda and Seagen and Astella’s Padcev has made noise as a possible option for untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.

article source
 

<



Similar threads

cafead
ESMO: Seagen and Genmab&#039;s Tivdak keeps cervical cancer patients alive longer
Replies
0
Views
143
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in...
Replies
0
Views
126
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update &amp; More
Replies
0
Views
152
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ESMO: Innovent links cytokine fusion protein to responses in colorectal cancer
Replies
0
Views
10
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ESMO-2024: Enhertu to eclipse the standard of care in HER2+ breast cancer with brain metastases
Replies
0
Views
3
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote